INTRODUCTION AND HYPOTHESIS: To quantify the prevalence (previous month) of urinary incontinence (UI) and overactive bladder (OAB), to assess its relation with known risk factors and to characterize UI awareness and treatment. METHODS: Telephone interviews were conducted in 1,934 Portuguese subjects aged > or =40 years. UI was defined according to the International Continence Society definitions. OAB was assessed through the Overactive Bladder Assessment Tool. RESULTS: The prevalence of UI was 21.4% (95% CI 19.0-23.9) in women, 7.6% (95% CI 4.8-10.4) in men. Diagnosis (ever in life) was reported by 4.5% (95% CI 3.3-5.7) of the participants, from which 73.0% reported to have been treated for UI. OAB was reported by 29.4% (95% CI 26.6-32.2) of women and 35.1% (95% CI 29.6-40.6) of men. Obesity, hysterectomy and asthma in women, and age in men, were significantly associated with the symptoms. CONCLUSIONS: UI and OAB prevalences were high, but the proportion of individuals aware of their condition was low, emphasizing the need for better information among physicians and general population.
INTRODUCTION AND HYPOTHESIS: To quantify the prevalence (previous month) of urinary incontinence (UI) and overactive bladder (OAB), to assess its relation with known risk factors and to characterize UI awareness and treatment. METHODS: Telephone interviews were conducted in 1,934 Portuguese subjects aged > or =40 years. UI was defined according to the International Continence Society definitions. OAB was assessed through the Overactive Bladder Assessment Tool. RESULTS: The prevalence of UI was 21.4% (95% CI 19.0-23.9) in women, 7.6% (95% CI 4.8-10.4) in men. Diagnosis (ever in life) was reported by 4.5% (95% CI 3.3-5.7) of the participants, from which 73.0% reported to have been treated for UI. OAB was reported by 29.4% (95% CI 26.6-32.2) of women and 35.1% (95% CI 29.6-40.6) of men. Obesity, hysterectomy and asthma in women, and age in men, were significantly associated with the symptoms. CONCLUSIONS: UI and OAB prevalences were high, but the proportion of individuals aware of their condition was low, emphasizing the need for better information among physicians and general population.
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696
Authors: Karin S Coyne; Teresa Zyczynski; Mary Kay Margolis; Victor Elinoff; Richard G Roberts Journal: Adv Ther Date: 2005 Jul-Aug Impact factor: 3.845
Authors: Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams Journal: Eur Urol Date: 2006-10-02 Impact factor: 20.096
Authors: W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein Journal: World J Urol Date: 2002-11-15 Impact factor: 4.226
Authors: Kraig S Kinchen; Kathryn Burgio; Ananias C Diokno; Nancy H Fultz; Richard Bump; Robert Obenchain Journal: J Womens Health (Larchmt) Date: 2003-09 Impact factor: 2.681
Authors: Symphorosa S C Chan; K W Choy; Beatrice P Y Lee; Selina M W Pang; Shing Kai Yip; Loreta L L Lee; Rachel Y K Cheung; Alice K W Yiu; Tony K H Chung Journal: Int Urogynecol J Date: 2010-02-19 Impact factor: 2.894
Authors: Ana Sa-Sousa; Mário Morais-Almeida; Luis Filipe Azevedo; Rosa Carvalho; Tiago Jacinto; Ana Todo-Bom; Carlos Loureiro; António Bugalho-Almeida; Jean Bousquet; João Almeida Fonseca Journal: Clin Transl Allergy Date: 2012-08-29 Impact factor: 5.871